The CCI Innovation Institute, established six years ago, boasts students in major hospitals and R&D institutions nationwide. It has effectively facilitated the transformation of numerous scientific and technological breakthroughs and products. Furthermore, it tremendously contributes to China's comprehensive cardiovascular technology innovation, technology research, clinical diagnosis and treatment, and industrial operations..
On November 24, 2021, Academician Ge Junbo's team at Zhongshan Hospital affiliated to Fudan University, achieved China's first clinical enrollment of ConFlow MedTech's FreeFlow® percutaneous atrial septal shunt system. Following the procedure, the patient experienced significant breakthroughs in heart failure symptoms, cardiac function, atrial function, reduced atrial pressure, increased cardiac output, decreased mitral regurgitation, and improved exercise tolerance. This successful operation introduces a new treatment option for heart failure patients, complementing conventional drug therapy.
The FreeFlow® percutaneous atrial septal shunt system is a heart failure treatment device created by ConFlow MedTech founded by Ms. Chen Xiumin, a sixth-term member of CCI Innovation Institute. This pioneering device, represents China's inaugural percutaneous atrial septal shunt system featuring rapid endothelialization through a polymer membrane and secondary recycling. Its distinctive elliptical design minimizes implant volume and allows for compatibility with a smaller delivery system.
The FreeFlow® percutaneous atrial septal shunt system technology was initially patented by Academician Ge Junbo, Director Zhou Daxin, and Professor Guan Lihua of Zhongshan Hospital Affiliated to Fudan University in 2016. Building upon this patent, ConFlow MedTech further developed and expanded the design, investing significant resources in research and development. This effort resulted in multiple patents, establishing complete and independent intellectual property rights for this genuinely original Chinese technology.
Ms. Chen Xiumin, a sixth-term member of CCI Innovation Institute, boasts over a decade of experience in structural heart disease. She's well-versed in the entire process of medical device projects, from company inception and team formation to product design, development, and testing, including preclinical and registered clinical trials. She's also skilled in product marketing, sales, project investment, financing, and company IPOs. Ms. Chen Xiumin is committed to hard work, innovation, and addressing gaps in China's innovative treatment product landscape. Leveraging the collaborative platform between CCI clinicians and a professional R&D team, she tirelessly conducts cutting-edge high-tech research and clinical transformations. This ensures that Chinese patients can access top-notch international treatments and services without delay.
A sixth-term member of CCI Innovation Institute - Ms. Chen Xiumin
The future has arrived, and it is in the NOW. Amidst this wave of scientific and technological advancements, we aspire for every dedicated individual in the medical field to contribute their unique expertise to advance China's innovative healthcare. Together, let's work towards a brighter future for China's cardiovascular industry.
-
July 01,2023ConFlow MedTech's registration for the 2023 CSI Frankfurt International Summit debut.
-
October 11,20222022 China Structural Heart Disease Academic Week｜Clinical progress of FreeFlow shunt in the treatment of right heart failure
-
May 09,2023Academician Ge Junbo's team has completed the first clinical enrollment of TriFlower new type foramen ovale obturator in China!
Pursue further excellence!
